Theralase Technologies Inc. V.TLT

13 & 14

[fredgoodwinson]

Wondering whether if the 30 day results for Ps 13 & 14 weren’t as conclusively positive as they were for P6 they’d have proceeded with the rollout in the States in the light of the false start and whether if - as the Inspector suggests - they need a further cap raise to fund this expansion they might feel able to release interim results (if positive) for 13 & 14 to boost the sp in advance rather than waiting for the second treatments?

[skys1]

They have said several times they have enough cash to last through this Ph 2 trial. Considering  they have substantially reduced operating costs by cutting about half of the payroll during the pandemic, they should be in a good current cash condition to finish this.

[fredgoodwinson]

In that case it`ll likely be after the second treatment (around June time?) before we get outcomes for these.

[CancerSlayer]

That's a lot of supposition Fred ; ).   More than likely they are simply waiting for data on a larger or more statistically significant cohort of "optimized" patients before the release of any results.  For me, the more telling/important CR data will be at 9 months...unless 9 month data are simply confirmatory & indicate a high rate of CRs post the first treatment

[fredgoodwinson]

Hi CancerSlayer Tbh don`t think that they`re obliged to let us know even then and that we may have to wait for the enduring CRs at 12 months so that could be long away. Really thinking how to get the sp to nearer where it should be in the event that they need more cash - not forgetting that they may (in theory anyway!) start Clinical Trials in two new indications this year. Anyway if that`s not

[CancerSlayer]

Agree... In terms of the "9 month" data, I referenced that point in time simply from a scientific/PI perspective...it wouldn't be reported, but it certainly would be a good early indicator of protocol success in the event there isn't a high "early" CR rate.  With a limited budget, I honestly hope they make significantly more progress on this trial & with the

[patience69]

Maybe it is the elephant in the room but does anyone consider the option of a complete buyout? Not now but when we get more substantial & positive data on phase 2 NMIBC. We all know that funding other indication trials could prove very challenging.  If we did a deal with Lumeda/Roswell & then something with someone else for GBM would that not be shooting ourselves in the foot as big

[Longholder99]

I'd be ok with 5B. Wouldnt be what the tech is actually worth but IMO that translates to around 15 bucks a share.....so ya.

[charlierock]

I would fully expect a buyout or possibly a joint venture. No one can predict when that would happen but I would be pissed if happened with out an increase of many multiples in the share price first.

[CancerSlayer]

Agree...Go Big with Pharma (buyout) or go home imo.  I don't want to see any JV, multiple partners or sharing of any kind, especially if you want to be "assured" immediate & longer term commercial benefits.  If needed, Pharma would certainly keep specific expertise in the technology/dosimetry on board.  The biggest challenge may no longer be in scientific execution

[skys1]

patience69 - Absolutely. A deal is more than a real possibility. IMO, it's a probablility once they can get the CR rate above 60% which I fully expect, Big Pharma will not be able to continue to sit on the sidelines and watch as they would know they could get left behind as cancer treatment is rapidly becoming one of the most profitable areas of medicine. Not to mention the multi applications